Novo Nordisk A/S’s weight-loss and diabetes drugs ... It’s also a sign that the billions of dollars the drugmaker has poured into factory construction are paying off. That puts the Danish ...

Novo Nordisk announced that its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes lose 15.7% of their weight in a recent trial. That figure ...

Novo Nordisk (NVO) is not concerned by the ongoing ... next step in the supply chain — a $4.1 billion fill-and-finish factory — nearby. The process for APIs involves large tanks that ...

Novo Nordisk (NYSE: NVO) shareholders know all about the ups and downs of pharmaceutical stock investing. From the beginning of the coronavirus pandemic through the middle of last June ...

The CEO of <strong>Novo Nordisk</strong> warned of the impact of tariffs on the pharmaceutical industry. Weight-loss drugs, including Ozempic and Wegovy, could cost ...

This is centered on its hotly popular drug Wegovy. Before market open, Novo Nordisk announced the launch of its NovoCare Pharmacy, a direct-to-patient delivery service for its best-selling Wegovy ...

Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial. Novo's results from its Redefine 2 late-stage trial of ...